



Article

Galectin-3 and Blood Group: Binding Properties, Effects on Plasma Levels, and Consequences for Prognostic Performance

Carolin Pozder ^{1,†}, Elles M. Screever ^{1,2,†}, A. Rogier van der Velde ¹, Herman H. Silljé ¹ , Janne Suwijn ^{3,4}, Saskia de Rond ^{3,4}, Marcus E. Kleber ^{3,4}, Graciela Delgado ³, Jan Jacob Schuringa ⁵, Wiek H. van Gilst ¹, Wouter C. Meijers ^{1,2,*}, Winfried März ^{3,6} and Rudolf A. de Boer ^{1,2}

¹ Department of Cardiology, University Medical Center Groningen, University of Groningen, 9700 RB Groningen, The Netherlands

² Department of Cardiology, Thorax Center, Erasmus University Medical Center, P.O. Box 2040, 3000 CA Rotterdam, The Netherlands

³ Mannheim Medical Faculty, Medical Clinic V (Nephrology, Hypertensiology, Endocrinology, Diabetology, Rheumatology), University of Heidelberg, 68167 Mannheim, Germany

⁴ SYNLAB MVZ Humangenetik Mannheim, 68163 Mannheim, Germany

⁵ Department of Experimental Hematology, University Medical Center Groningen, University of Groningen, 9700 RB Groningen, The Netherlands

⁶ Synlab Academy, SYNLAB Holding Deutschland GmbH, 68159 Mannheim, Germany

* Correspondence: w.meijers@erasmusmc.nl

† These authors contributed equally to this work.



Citation: Pozder, C.; Screever, E.M.; van der Velde, A.R.; Silljé, H.H.; Suwijn, J.; de Rond, S.; Kleber, M.E.; Delgado, G.; Schuringa, J.J.; van Gilst, W.H.; et al. Galectin-3 and Blood Group: Binding Properties, Effects on Plasma Levels, and Consequences for Prognostic Performance. *Int. J. Mol. Sci.* **2023**, *24*, 4415. <https://doi.org/10.3390/ijms24054415>

Academic Editors: Domenica Capasso, Emilia Maria Pedone and Sonia Di Gaetano

Received: 23 December 2022

Revised: 8 February 2023

Accepted: 14 February 2023

Published: 23 February 2023



Copyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

Abstract: Previous studies have reported an association between ABO type blood group and cardiovascular (CV) events and outcomes. The precise mechanisms underpinning this striking observation remain unknown, although differences in von Willebrand factor (VWF) plasma levels have been proposed as an explanation. Recently, galectin-3 was identified as an endogenous ligand of VWF and red blood cells (RBCs) and, therefore, we aimed to explore the role of galectin-3 in different blood groups. Two in vitro assays were used to assess the binding capacity of galectin-3 to RBCs and VWF in different blood groups. Additionally, plasma levels of galectin-3 were measured in different blood groups in the Ludwigshafen Risk and Cardiovascular Health (LURIC) study (2571 patients hospitalized for coronary angiography) and validated in a community-based cohort of the Prevention of Renal and Vascular End-stage Disease (PREVEND) study (3552 participants). To determine the prognostic value of galectin-3 in different blood groups, logistic regression and cox regression models were used with all-cause mortality as the primary outcome. First, we demonstrated that galectin-3 has a higher binding capacity for RBCs and VWF in non-O blood groups, compared to blood group O. Additionally, LURIC patients with non-O blood groups had substantially lower plasma levels of galectin-3 (15.0, 14.9, and 14.0 µg/L in blood groups A, B, and AB, respectively, compared to 17.1 µg/L in blood group O, $p < 0.0001$). Finally, the independent prognostic value of galectin-3 for all-cause mortality showed a non-significant trend towards higher mortality in non-O blood groups. Although plasma galectin-3 levels are lower in non-O blood groups, the prognostic value of galectin-3 is also present in subjects with a non-O blood group. We conclude that physical interaction between galectin-3 and blood group epitopes may modulate galectin-3, which may affect its performance as a biomarker and its biological activity.

Keywords: biomarker; galectin-3; blood group; von Willebrand factor; prognosis

1. Introduction

Cardiovascular (CV) diseases account for 32% of global deaths, and the prognosis of patients with CV disease, particularly in patients with heart failure, remains poor; it is, therefore, important to further investigate disease characteristics and identify risk factors that can serve as therapeutic targets [1,2]. Besides the classical risk factors of heart

failure such as hypertension, smoking, dyslipidaemia, obesity, and diabetes mellitus, a sedentary habit, excessive alcohol intake, influenza, certain microbes, cardiotoxic drugs, chest radiation, and coronary artery disease also have to be considered [3,4]. However, the residual risk remains high, and we do not fully understand all factors contributing to CV disease development.

In the past years, the ABO blood group has been identified as a novel and intriguing risk factor for CV disease. Multiple studies have shown an association between non-O blood groups and the risk of different thromboembolic events [5], coronary heart disease [6], the size of a myocardial infarction after an acute coronary syndrome [7], increased mortality in patients with ischemic heart disease [8], and venous thrombosis [9]. The exact mechanisms behind these associations remain unclear to date, but as a possible common mechanism, variable levels and activity of the von Willebrand Factor (VWF) have been proposed. VWF is widely acknowledged as a key determinant in CV homeostasis and has been linked to thrombosis and CV events [10,11]. VWF was also found to be a binding partner of galectin-3 [12].

Galectin-3 is a carbohydrate-binding protein and has been shown to be involved in inflammation, cancer, and CV disease [13–17]. It was shown that galectin-3 is able to modulate VWF-mediated thrombus formation via a direct (physical) interaction with VWF [12]. A possible link between galectin-3 and blood group has been described previously—a genome-wide association study showed that the ABO gene locus was strongly associated with plasma galectin-3 levels [18]. This ABO locus appears to be a very pleiotropic locus that associates with several CV traits [19]. Building upon those findings, we hypothesized that ABO, galectin-3, and VWF would interact and, specifically, that the described associations between galectin-3 and CV outcome [20] can, at least partially, be explained by an interaction with the ABO blood group and VWF levels.

2. Results

2.1. Study Population

The baseline characteristics of patients in the LURIC study are presented in Table 1. The mean age (SD) was 63 (10) years, and the majority of the population was male (68%). Out of the population, 946 (37%) of the patients had blood group O, 1219 (47%) blood group A, 276 (11%) blood group B, and 130 (5%) blood group AB. Additionally, 495 (19%) of the patients were smokers, and a medical history of hypertension and coronary artery disease were very common (73% and 77%, respectively). To validate our findings, we studied the relationship between galectin-3 and the blood group in a community-based cohort, for which we used the PREVEND study. Participants of the PREVEND cohort were younger (mean age 50 ± 12), and sex was equally distributed (51% male versus 49% female). 1557 (44%) had blood group O, 1606 (45%) blood group A, 271 (8%) blood group B, and 118 (3%) blood group AB. Smoking was common (46%), but hypertension was less abundant compared to the LURIC cohort (30%), as expected (Supplemental Table S1).

Table 1. Baseline characteristics of the LURIC study participants, stratified by ABO blood group.

Clinical Characteristics	Total	Blood Group O	Blood Group A	Blood Group B	Blood Group AB	p-Value
	(n = 2571)	(n = 946)	(n = 1219)	(n = 276)	(n = 130)	
Age (y), mean (SD)	63 (10)	63 (10)	63 (11)	63 (11)	62 (11)	0.68
Male sex, n (%)	1756 (68)	642 (68)	842 (69)	187 (68)	85 (65)	0.81
Current smoker, n (%)	495 (19)	201 (21)	211 (17)	57 (21)	26 (20)	0.12
BMI (kg/m ²), mean (SD)	278 (4)	28 (4)	27 (4)	27 (4)	27 (3)	0.08
Heart rate (bpm), median [IQR]	68 [61–75]	68 [61–75]	68 [61–76]	66 [60–74]	66 [60–76]	0.40
Systolic blood pressure, median [IQR]	140 [123–157]	142 [123–158]	140 [124–156]	140 [123–158]	136 [121–152]	0.30
Diastolic blood pressure, median [IQR]	81 [73–88]	81 [73–89]	80 [73–88]	81 [73–90]	80 [72–89]	0.89
Medical history, n (%)						
Type 2 diabetes mellitus	1032 (40)	372 (39)	507 (42)	104 (38)	49 (38)	0.50
(History of) hypertension	1865 (73)	691 (73)	880 (72)	200 (72)	91 (70)	0.90
(History of) coronary artery disease	1986 (77)	720 (76)	949 (78)	216 (78)	96 (74)	0.59

Table 1. Cont.

Clinical Characteristics	Total	Blood Group O	Blood Group A	Blood Group B	Blood Group AB	p-Value
Laboratory measurements						
eGFR (MDRD), median [IQR]	81 [69–92]	80 [68–91]	81 [70–93]	80 [70–92]	81 [70–92]	0.11
Glucose (mmol/L), median [IQR]	5.7 [5.2–6.6]	5.7 [5.2–6.6]	5.7 [5.2–6.6]	5.7 [5.2–6.6]	5.6 [5.2–6.3]	0.62
Cholesterol (mmol/L), median [IQR]	4.9 [4.3–5.6]	4.9 [4.2–5.5]	4.9 [4.3–5.7]	4.9 [4.4–5.6]	4.8 [4.2–5.4]	0.25
LDL (mmol/L), median [IQR]	2.9 [2.4–3.6]	2.9 [2.4–3.5]	3.0 [2.4–3.6]	3.0 [2.5–3.6]	2.9 [2.3–3.5]	0.16
HDL (mmol/L), median [IQR]	1.0 [0.8–1.2]	1.0 [0.8–1.2]	1.0 [0.8–1.2]	1.0 [0.8–1.2]	1.0 [0.8–1.2]	0.39
Triglycerides (mmol/L), median [IQR]	3.8 [2.8–5.2]	3.9 [2.8–5.3]	3.7 [2.7–5.1]	3.7 [2.8–5.2]	3.6 [2.6–5.0]	0.28
NT-proBNP (ng/L), median [IQR]	296 [108–884]	286 [104–895]	299 [109–907]	345 [112–873]	292 [104–733]	0.70
Galectin-3 (µg/L), mean (SD)	15.7 (7.0)	17.1 (7.4)	15.0 (6.7)	14.9 (6.6)	14.0 (6.1)	<0.001
VWF (U/dL), median [IQR]	156 [120–198]	132 [100–176]	165 [130–206]	176 [136–214]	189 [145–228]	<0.001

Abbreviations: BMI, body mass index; bpm, beats per minute; eGFR, estimated glomerular filtration rate; IQR, interquartile range; HDL, high-density lipoprotein; LDL, low-density lipoprotein; MDRD, Modification of Diet in Renal Disease; NT-proBNP, N-terminal pro-B-type natriuretic peptide; SD, standard deviation; VWF, von Willebrand Factor.

2.2. Galectin-3 Plasma Levels Stratified by Blood Group

The LURIC cohort was stratified by blood group. Plasma levels of galectin-3 were significantly higher in blood group O compared to other blood groups ($p < 0.0001$ for all groups versus blood group O) (Table 1, Figure 1A). Furthermore, VWF levels were significantly lower in blood group O compared to other blood groups (Table 1). In the PREVEND cohort, galectin-3 levels were also significantly different among blood groups and showed the highest values in blood group O compared to other blood groups (Figure 1B, Supplemental Table S1). Moreover, subjects with homozygous blood groups showed a trend towards lower plasma levels of galectin-3 compared to subjects with heterozygous blood groups (Supplemental Figure S1).




Figure 1. Plasma galectin-3 levels in (A) LURIC and (B) PREVEND participants, stratified by ABO blood group. Data is presented as mean \pm SEM. **** $p < 0.0001$ compared to blood group O (Dunn's multiple comparisons test).

2.3. Binding of Galectin-3 and Red Blood Cells

Galectin-3 is known to mediate the hemagglutination of red blood cells (RBCs). To further characterize a potential interaction between galectin-3, VWF, and blood group, two different in vitro assays were performed. The first assay was a hemagglutination assay, to examine the interaction between galectin-3 and the blood group, as displayed in Supplemental Figure S2. With this assay we showed that the binding of galectin-3 with RBCs was significantly different between blood groups, with RBCs from blood group O binding less galectin-3 compared to all other blood groups (Figure 2A,B).




Figure 2. (A) Galectin-3-mediated hemagglutination of blood from different blood groups. (B) Hemagglutination induced by 0.5 μM galectin-3. (C) Galectin-3 binding to VWF in different blood groups, as assessed by measuring absorbance at 450 nm. * $p < 0.05$ compared to blood group O; ** $p < 0.01$ compared to blood group O; *** $p < 0.001$ compared to blood group O. Abbreviations: HA-index, hemagglutination-index.

2.4. Interaction between VWF and Galectin-3

Since galectin-3 has been presented as a partner for VWF, we assessed the binding of VWF with galectin-3 in different blood groups using a VWF-galectin-3 binding assay. Blood plasma with similar levels of VWF (as determined with ELISA) was equalized to similar concentrations with 0.9% NaCl and incubated in a plate coated with galectin-3. Using VWF antibodies, the galectin-3-VWF binding was detected. This assay showed that the binding for galectin-3 to VWF was stronger in all non-O blood groups compared to blood group O (Figure 2C).

2.5. Prognostic Value of Galectin-3

We studied the prognostic value of galectin-3 in different blood groups in the LURIC study cohort. During a median follow-up time of 9.8 [8.6–10.4] years, 758 deaths (29%) were observed. Using Cox regression analyses, galectin-3 remained a significant predictor for all-cause mortality, even after multivariate adjustment (HR 1.89 [1.28–2.79] and HR 2.19 [1.67–2.86] in blood group O and blood group non-O, respectively) (Table 2). The HR is higher in non-O blood groups, although galectin-3 plasma levels were lower in these patients (Figure 3A).

Table 2. Cox proportional hazard analyses of log-transformed galectin-3 for the risk on all-cause mortality, divided by blood group.

LURIC Study	Blood Group O	<i>p</i> -Value	Blood Group Non-O	<i>p</i> -Value	<i>p</i> -Value for Interaction
All-cause mortality	HR [95% CI]		HR [95% CI]		
Galectin-3	2.73 [2.03–3.67]	<0.001	3.06 [2.45–3.83]	<0.001	0.53
Galectin-3	2.31 [1.65–3.24]	<0.001	2.20 [1.73–2.80]	<0.001	0.78
+sex & age					
Galectin-3	1.89 [1.28–2.79]	0.001	2.19 [1.67–2.86]	<0.001	0.89
+fully adjusted *					
PREVEND Study	Blood Group O	<i>p</i> -Value	Blood Group Non-O	<i>p</i> -Value	<i>p</i> -Value for Interaction
All-cause mortality	HR [95% CI]		HR [95% CI]		
Galectin-3	2.48 [1.70–3.63]	<0.0001	3.44 [2.45–4.84]	<0.0001	0.20
Galectin-3	1.31 [0.74–2.32]	0.35	1.87 [1.16–3.03]	0.010	0.28
+sex & age					
Galectin-3	1.05 [0.53–2.09]	0.87	1.44 [0.83–2.48]	0.20	0.82
+fully adjusted *					

* Adjusted for age, sex, eGFR, smoking, systolic blood pressure, BMI, LDL-cholesterol, diabetes mellitus, lipid lowering therapy, triglycerides, and CRP. Abbreviations: CI, confidence interval; HR, hazard ratio.




Figure 3. Graphical illustration of the probability of death by log-galectin-3 levels, in subjects with blood group O (blue) and blood group non-O (orange), depicted on left *y*-axis. Data are presented as adjusted splines of predicted Odds Ratio. The histograms represent the percentage of subjects with that specific log-galectin-3 level in subjects with blood group O (blue) and blood group non-O (orange), depicted on right *y*-axis. (A) Probability of death in LURIC cohort. Odds ratio 1.77 [1.07–2.93] and 2.35 [1.64–3.36] in blood group O and blood group non-O, $p = 0.026$ and $p < 0.0001$, respectively. (B) Probability of death in PREVEND cohort. Odds ratio 0.94 [0.42–2.10] and 1.48 [0.77–2.87] in blood group O and blood group non-O, $p = 0.887$ and $p = 0.241$, respectively. A similar increase in galectin-3 has more prognostic value in subjects with non-O blood group compared to subjects with blood group O. Data are adjusted for age, sex, eGFR, smoking, systolic blood pressure, BMI, LDL-cholesterol, diabetes mellitus, lipid lowering therapy, triglycerides, and CRP.

We also assessed the prognostic value of galectin-3 among different blood groups in the general population after adjustment for the same variables. In the PREVEND study, the median follow-up time was 12.6 [12.3–12.9] years, and 353 subjects (10%) died during this period. The same trend was observed compared to the LURIC study: galectin-3 appeared to have a higher prognostic value regarding all-cause mortality in non-O blood groups (Figure 3B), although the *p* for interaction was non-significant. The blood group itself was not an independent predictor for outcome in both the LURIC and PREVEND study cohorts (Supplemental Table S2).

3. Discussion

We demonstrate that circulating galectin-3 levels in subjects with non-O blood groups are significantly lower compared to levels in subjects with blood group O. However, the prognostic value of galectin-3 is stronger in subjects with non-O blood groups. As a potential mechanism, we propose that VWF may mediate this, as circulating VWF and galectin-3 were inversely related. We demonstrate that galectin-3 binds stronger to RBCs and VWF of subjects with non-O blood groups compared to subjects with blood group O.

Accumulating evidence suggests that the ABO blood group is involved in the pathogenesis of CV disease and that non-O blood groups had the highest risk of CV disease [19,21]. Previous studies have shown that the presence of non-O blood groups is associated with worse outcomes compared to blood group O [21–24]. In a recent case-control study consisting of 165 centenarians and 5063 blood donors from the same geographical region, it was observed that among centenarians the prevalence of blood group O was higher (56.4% vs. 43.5%; *p* = 0.001) [25]. Besides studies that demonstrate a higher CV risk for non-O blood groups, there are a few studies that specifically found the highest risk, for blood group A and blood group AB [6,21,26–29]. For example, one recent Finnish study found the highest risk of ischaemic heart disease in a patient with blood group A with T1DM and microalbuminuria [27]. A Canadian study (*n* = 64,686) demonstrated that blood group AB is associated with an increased risk of thrombotic events in participants from Quebec [28].

The ABO(H) blood group is the most important blood group system and is determined by complex carbohydrate moieties at the extracellular surface of the RBC membrane [30]. The A and B alleles encode for either A- or B-glycosyltransferases that add *N*-acetylgalactosamine or D-galactose to the common H-glycan precursor backbone, respectively. In subjects with blood group O, no A- or B-transferase activity is present, resulting in the expression of the H-glycan backbone without an additional group [31]. Next to the expression of RBCs, these blood group epitopes and different antigens are also expressed on other cells, such as the vascular endothelium, epithelial cells, T-cells, B-cells, and platelets, and present on molecules such as VWF [32,33].

Several studies described the major effects of the ABO blood group on plasma levels of VWF: plasma VWF levels appear to be 25% lower in the O blood group compared to non-O blood groups [6]. This implies that subjects with blood group O may experience a higher incidence of bleeding events, while subjects with non-O blood groups experience a higher incidence of thrombotic events [34,35]. The exact mechanisms underpinning these observations remain unclear, but this effect may be mediated by VWF. The effect of the ABO blood group on plasma levels of VWF seems to be the result of a direct effect of the ABO blood group [36]. The conversion of the blood group O determinant into other antigens of the ABO blood group was correlated with an increased capacity to modify the N-linked glycosylation of VWF [37]. Therefore, changes in VWF glycan composition also affect the biological activity of VWF and are not restricted to its plasma levels [38]. Carbohydrate structures on the surface of VWF play an important role in the life cycle of VWF. Galectin-3 is a carbohydrate-binding protein and has recently been identified as a new partner of VWF [12]. Furthermore, the affinity of transmembrane glycoproteins to the galectin-3 molecule is proportional to the number and branching of their N-glycans [39]. Therefore, we hypothesize that the biological activity of galectin-3 might also be directly regulated by the glycosylation of the molecule by the ABO blood group.

In agreement with previous studies, we confirmed that plasma VWF levels are ~25% higher in non-O blood groups. Additionally, we now show in two independent cohorts with different populations, that galectin-3 levels are significantly lower in non-O blood groups. Furthermore, we show that galectin-3 levels are lower in patients who had a heterozygous blood group. This inverse relationship between galectin-3 and VWF levels in different blood groups is an interesting phenomenon, potentially explained by the fact they are ligands of each other.

Numerous studies have assessed the prognostic value of galectin-3 in various cohorts [40–42]. We again corroborated these findings in the current study and herein confirm that galectin-3 is an independent predictor for all-cause mortality, particularly in subjects with non-O blood groups. The striking observation that galectin-3 has a strong prognostic value in non-O blood groups, although the group has lower galectin-3 values, should be explored in further detail. We speculate that the observed lower galectin-3 plasma values in the non-O blood group participants are caused by galectin-3 binding with blood group epitopes and that glycosylation might play a role in this.

In two different in vitro assays, we show a higher binding capacity of galectin-3 with RBCs and VWF in subjects with non-O blood groups, compared to blood group O. Binding preference of galectin-3 is most likely related to the extensive glycosylation of VWF, generating a clustered glycan surface, resembling the cell membrane [12]. These protein-glycan interactions between VWF and galectin-3 mainly consist of binding patterns with *N*-linked glycans rather than *O*-linked glycans, as has been shown previously [43]. Galectins regularly show a high affinity for glycans with longer poly-*N*-acetylactosamine (poly-LacNAc) chains, given their higher binding capacity for *N*-linked glycans.

The higher hemagglutination activity in subjects with non-O blood groups is consistent with previous findings from erythrocyte binding and glycan microarray studies, suggesting that galectin-3 exhibits higher binding towards blood group A and B antigens compared to those bearing the H antigen [43–46]. While all galectins show a high affinity for β -galactosides, their recognition following terminal glycan modifications varies. The enhanced recognition of galectin-3 towards A and B blood group substitutions is potentially caused by unique subsides within the carbohydrate recognition domain (CRD) [43] and might play an evolutionary role. In fact, it enables the targeting of microbes that utilize blood group molecular mimicry [47]. Additionally, we hypothesize that stronger binding of galectin-3 with RBCs and VWF in non-O blood groups could explain lower levels of circulating galectin-3.

The prognostic value and absolute levels of biomarkers may differ between different subgroups in a study cohort, as previously observed for other biomarkers [48]. For instance, plasma levels differ between sexes, and also age, renal function, and the presence of diabetes are important determinants of hemoglobin level [49,50]. Even for the established cardiac marker NT-proBNP, important determinants exist leading to differences in circulating levels; renal failure tends to increase natriuretic peptide levels, whereas patients with obesity show lower levels of NT-proBNP [51,52]. Using a combination of biomarkers might improve risk prediction of clinical outcomes and, therefore, healthcare-related costs.

In conclusion, we postulate that the binding of galectin-3 to the A-, B-, and AB-blood group epitopes affects the circulating plasma levels and its biological activity, and thereby also its prognostic power for a given concentration. Future studies should provide more detailed data on this interaction and practical information on how to deal with this potential confounder.

4. Materials and Methods

4.1. Study Population

4.1.1. LURIC

The Ludwigshafen Risk and Cardiovascular Health (LURIC) study consists of 3316 patients who were hospitalized for coronary angiography between 1997 and 2000. Indications for coronary angiography were chest pain or a positive non-invasive stress test suggestive of

myocardial ischemia. Further methods and results have been described previously [53]. In total, galectin-3 values and blood group information were available for 2571 patients.

4.1.2. PREVEND

The Prevention of Renal and Vascular End-stage Disease (PREVEND) study is a prospective, observational, community-based study and was used to validate our findings [18,54]. The PREVEND study enrolled community-dwelling subjects during 1997–1998, and the study was designed to track the long-term development of cardiac, renal, and peripheral vascular disease. More details of the design of the study have been described previously [55,56]. Galectin-3 and blood group data were available in 3552 subjects.

In both studies, all participants provided informed consent, and the study procedures were conducted in accordance with the 1975 Declaration of Helsinki. The LURIC study was approved by the ethical committee of the Ärztekammer Rheinland-Pfalz, and the PREVEND study was approved by the ethical committee of the University Medical Center Groningen (UMCG).

4.2. Galectin-3 Measurements

In the LURIC study, galectin-3 levels were measured in plasma samples from the baseline. These samples were stored at -80°C and were analysed using the ARCHITECT analyser (Abbott Diagnostics, Abbott Park, IL, USA). This automated assay uses the same antibodies and conjugates as in the manual assay and has a lower limit of detection of 1.01 ng/mL. Intra- and inter-assay variability are 3.2% and 0.8%, respectively [57]. In the PREVEND study, blood was drawn at the baseline and anticoagulated with EDTA. Samples were stored at -80°C until the time of analysis. Galectin-3 concentration was measured in plasma samples from the baseline using the BGM galectin-3 ELISA kit (BG Medicine Inc., Waltham, MA, USA). Intra- and inter-assay coefficients of this assay are 3.2% and 5.6%, respectively. The assay has a lower limit of detection of 1.13 ng/mL and did not show cross-reactivity with collagens or other members of the galectin family [58].

4.3. Blood Group Determination

Blood group in LURIC was determined in the Haemostaseology Laboratory of the Ludwigshafen Cardiac Centre using a blood group antisera macroscopic agglutination assay (ABO- and Rh-blood group sera, Loxo GmbH, Dossenheim, Germany). In the PREVEND cohort, the ABO blood group was inferred from genotyping three single nucleotide polymorphisms (SNPs) on the ABO gene, namely rs8176719, rs8176746, and rs8176747. Using a combination of these SNPs, a blood group could be determined, as described previously [59].

4.4. Clinical Endpoints

In LURIC, mortality data were collected from local registries. Two independent and experienced clinicians, who were blinded for patient characteristics, reviewed information from death certificates, medical records from hospitals, and data from autopsies [20,60]. In PREVEND, mortality data were collected using the municipal register, and cause of death was obtained using the Prisma health care data system or Dutch Central Bureau of Statistics. Follow-up times ranged from the last follow-up or were censored on the date of the event or last contact, whatever occurred first.

4.5. In Vitro Studies

4.5.1. Isolation of Red Blood Cells

Neonatal cord blood was obtained from healthy full-term pregnancies from donors from the obstetrics departments of the Martini Hospital Groningen and UMCG after informed consent was given. All donors were informed about the studies that were performed, as approved by the local Medical Ethical Committee of the UMCG. Furthermore, healthy volunteers from the research lab also provided blood specimens. Blood was

collected in 10 mL EDTA tubes and 20 μ L of blood was used to determine the ABO blood group using a Serafol ABO bedside test (Bio-Rad Laboratories BV, Veenendaal, the Netherlands). The remaining blood was centrifuged at 3500 rpm for 5 min. The buffy coat appeared as a dense white layer in the middle between the RBCs and plasma. Plasma and the buffy coat were removed from the tube. RBCs remained in the tube and were resuspended in PBS and again centrifuged at 2000 rpm for 5 min at 4 °C. This washing step was repeated 3 times. Subsequently, the remaining RBCs were diluted 12.5 \times in PBS-3% glutaraldehyde in a tube, and this was put on a rotating wheel for 1 h at room temperature. Afterwards, the cells were washed 5 times with PBS (0.0025% NaN₃) and centrifuged at 2000 rpm for 2 min at 4 °C, and in the last step, cells were resuspended at 3–4% in PBS (0.0025% NaN₃). Cells were stored at 4 °C for several days.

4.5.2. Hemagglutination Assay

RBCs were counted using a Fuchs-Rosenthal counting chamber. All cells were diluted to the lowest concentration of RBCs. We first calibrated our hemagglutination assay to determine the number of RBCs that were needed to show hemagglutination and to clearly distinguish between agglutinated and non-agglutinated cells. We tested 3 different concentrations of RBCs (5 μ L/10 μ L/15 μ L of 2000 cells/ μ L) and 2 concentrations of galectin-3 (1 μ M/2 μ M). Following calibration, we used 15 μ L RBCs/2 μ M galectin-3 in the first well of a round-bottom, 96-well plate (Costar #3799, Corning Inc., Kennebunk, ME, USA). Next, 2 μ M galectin-3 was serially diluted 1:1 into the next wells and 87.5 μ L PBS was added to a total volume of 185 μ L. Finally, 15 μ L (2000 cells/ μ L) of RBCs were added to each well. The plate was incubated for 30 min at 4 °C and pictures were made using the ImageQuant LAS 4000 (GE Healthcare, Europe GmbH, Diegem, Belgium). Hemagglutination was assessed using ImageJ software (Version 1.50, National Institutes of Health, Bethesda, MD, USA), and the hemagglutination-index ((surface area of RBCs after incubation/surface area of the total well) \times 100) (HA-index) was calculated.

4.5.3. Von Willebrand Factor ELISA

VWF was measured in human plasma using the VWF ELISA kit (Abcam, Cambridge, UK). This kit was designed for the quantitative measurement of human VWF in plasma, serum, and cell culture supernatants. Intra- and inter-assay coefficients of variation of this assay are 5% and 7.1%, respectively. The lower level of detection is 2.5 mU/mL.

In LURIC, VWF was measured using the STA Liatest®VWF assay (Stago Diagnostica/Roche, Mannheim, Germany).

4.5.4. Galectin-3—von Willebrand Factor Binding Study

As previously described [12], an immunosorbent assay was performed in which a microtiter 96-well plate was coated with galectin-3 (5 μ g/well) overnight at 4 °C. After washing 3 times with PBS (0.1% Tween-20) the plate was blocked for 2 h with PBS (0.1% Tween-20/3% BSA) at 37 °C. After washing 2 times with PBS (0.1% Tween-20), plasma of different blood groups was incubated in the wells for 1 h at 37 °C. After discarding the plasma, the plate was washed 2 times with PBS (0.1% Tween-20). Bound VWF was detected by adding 50 μ L HRP-labelled polyclonal VWF antibody (1:1000; P0226, DAKO, Glostrup, Denmark). 50 μ L 3,3',5,5'-tetramethylbenzidine (TMB) was added to detect HRP activity, and after 10 min 50 μ L of stop solution (H₂SO₄) was added to stop the reaction. The absorbance was measured using a microplate reader at a wavelength of 450 nm (BioTek Synergy H1, Winooski, VT, USA).

4.6. Statistical Analysis

Normally distributed variables are presented as means \pm standard deviation (SD) or standard error of the mean (SEM). Non-normally distributed variables are expressed as medians [interquartile range (IQR)]. To compare normally distributed values across two groups, a two-sample *t*-test was performed, and to compare non-normally distributed

values, we used the Wilcoxon rank-sum test. The comparison of categorical values was done using Pearson's Chi-square test. Characteristics across four groups were compared using the ANOVA for continuous and normally distributed values and the Kruskal-Wallis test for continuous, non-normally distributed values. In a comparison of >1 group with a control group, we used the Kruskal-Wallis with a post hoc Dunn's multiple comparisons tests.

Prior to analysis, galectin-3 was transformed logarithmically to obtain approximately normal distributions because of a skewed distribution as assessed by the Shapiro-Wilk test. To study the association of galectin-3 with all-cause mortality, Cox regression analysis and logistic regression analysis were performed with log-transformed galectin-3 as a continuous variable. The model was adjusted for age and sex and a multivariable model consisting of eGFR, smoking, systolic blood pressure, BMI, LDL-cholesterol, diabetes mellitus, lipid-lowering therapy, triglycerides, and CRP. This model is an established risk model for all-cause mortality in the LURIC study and has been used previously in other studies [20]. Results are stratified to blood group and summarized as hazard ratios, with 95% confidence intervals (CI). For the interaction term, a *p*-value of <0.10 was considered to indicate statistical significance. For all other analyses, *p*-values <0.05 were considered to be statistically significant. Analyses were performed using STATA software version 14.2 and GraphPad Prism version 9.3.1 (GraphPad Software Inc., La Jolla, CA, USA).

Supplementary Materials: The following supporting information can be downloaded at: <https://www.mdpi.com/article/10.3390/ijms24054415/s1>.

Author Contributions: C.P., E.M.S., A.R.v.d.V., H.H.S., J.S., S.d.R., M.E.K., G.D., J.J.S., W.H.v.G., W.C.M., W.M. and R.A.d.B. made substantial contributions to this article and were either involved in the conception of the work, the acquisition of data, the analysis or interpretation of data, drafted the work, or substantially revised the work. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported by grants from the Dutch Heart Foundation (CVON SHE-PREDICTS-HF, Grant 2017-21; CVON RED-CVD, Grant 2017-11; CVON PREDICT2, grant 2018-30; CVON DOUBLE DOSE, grant 2020B005; and grant 2000Z003), by a grant from the leDucq Foundation (Cure PhosphoLambaN induced Cardiomyopathy (Cure-PLaN)), and by a grant from the European Research Council (ERC CoG 818715, SECRETE-HF). Dr. Meijers is supported by the Mandema-Stipendium of the Junior Scientific Masterclass 2020-10 of the University Medical Center Groningen and by the Dutch Heart Foundation (Dekker grant 03-005-2021-T005). The funders had no role in the design and conduct of the study; collection, analysis, and interpretation of data; writing of the manuscript; and decision to submit the manuscript for publication.

Institutional Review Board Statement: The LURIC study was approved by the ethical committee of the Ärztekammer Rheinland-Pfalz and the PREVEND study was approved by the ethical committee of the University Medical Center Groningen (UMCG).

Informed Consent Statement: In both studies, all participants provided informed consent.

Data Availability Statement: Data will be made available upon request.

Conflicts of Interest: The UMCG, which employs/employed several of the authors, has received research grants and/or fees from AstraZeneca, Abbott, Boehringer Ingelheim, Cardior Pharmaceuticals GmbH, Ionis Pharmaceuticals, Inc., Novo Nordisk, and Roche. Rudolf A. de Boer received speaker fees from Abbott, AstraZeneca, Bayer, Novartis, and Roche. Wouter C. Meijers received speaker fees from Daiichi Sankyo and Novartis. The remaining authors declare no competing interests.

References

1. WHO. Cardiovascular Diseases (CVDs). Available online: <https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-cvds> (accessed on 4 December 2022).
2. Gerber, Y.; Weston, S.A.; Redfield, M.M.; Chamberlain, A.M.; Manemann, S.M.; Jiang, R.; Killian, J.M.; Roger, V.L. A contemporary appraisal of the heart failure epidemic in Olmsted County, Minnesota, 2000 to 2010. *JAMA Intern. Med.* **2015**, *175*, 996–1004. [CrossRef]
3. Vasan, R.S.; Sullivan, L.M.; Wilson, P.W.; Sempos, C.T.; Sundström, J.; Kannel, W.B.; Levy, D.; D'Agostino, R.B. Relative importance of borderline and elevated levels of coronary heart disease risk factors. *Ann. Intern. Med.* **2005**, *142*, 393–402. [CrossRef]

4. McDonagh, T.A.; Metra, M.; Adamo, M.; Gardner, R.S.; Baumbach, A.; Böhm, M.; Burri, H.; Butler, J.; Čelutkienė, J.; Chioncel, O.; et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur. Heart J.* **2021**, *42*, 3599–3726. [\[CrossRef\]](#)
5. Groot, H.E.; Sierra, L.E.V.; Said, M.A.; Lipsic, E.; Karper, J.C.; van der Harst, P. Genetically determined ABO blood group and its associations with health and disease. *Arterioscler. Thromb. Vasc. Biol.* **2020**, *40*, 830–838. [\[CrossRef\]](#)
6. He, M.; Wolpin, B.; Rexrode, K.; Manson, J.E.; Rimm, E.; Hu, F.B.; Qi, L. ABO blood group and risk of coronary heart disease in two prospective cohort studies. *Arterioscler. Thromb. Vasc. Biol.* **2012**, *32*, 2314–2320. [\[CrossRef\]](#)
7. Ketch, T.R.; Turner, S.J.; Sacrinty, M.T.; Lingle, K.C.; Applegate, R.J.; Kutcher, M.A.; Sane, D.C. ABO blood types: Influence on infarct size, procedural characteristics and prognosis. *Thromb. Res.* **2008**, *123*, 200–205. [\[CrossRef\]](#)
8. Carpeggiani, C.; Coceani, M.; Landi, P.; Michelassi, C.; L'abbate, A. ABO blood group alleles: A risk factor for coronary artery disease. An angiographic study. *Atherosclerosis* **2010**, *211*, 461–466. [\[CrossRef\]](#)
9. Franchini, M.; Favaloro, E.J.; Targher, G.; Lippi, G. ABO blood group, hypercoagulability, and cardiovascular and cancer risk. *Crit. Rev. Clin. Lab. Sci.* **2012**, *49*, 137–149. [\[CrossRef\]](#)
10. Vischer, U.M. von Willebrand factor, endothelial dysfunction, and cardiovascular disease. *J. Thromb. Haemost.* **2006**, *4*, 1186–1193. [\[CrossRef\]](#)
11. Spiel, A.O.; Gilbert, J.C.; Jilma, B. von Willebrand factor in cardiovascular disease: Focus on acute coronary syndromes. *Circulation* **2008**, *117*, 1449–1459. [\[CrossRef\]](#)
12. Saint-Lu, N.; Oortwijn, B.D.; Pegon, J.N.; Odouard, S.; Christophe, O.D.; de Groot, P.G.; Denis, C.V.; Lenting, P.J. Identification of galectin-1 and galectin-3 as novel partners for von Willebrand factor. *Arterioscler. Thromb. Vasc. Biol.* **2012**, *32*, 894–901. [\[CrossRef\]](#)
13. Martínez-Martínez, E.; Calvier, L.; Fernández-Celis, A.; Rousseau, E.; Jurado-López, R.; Rossoni, L.V.; Jaisser, F.; Zannad, F.; Rossignol, P.; Cachofeiro, V.; et al. Galectin-3 Blockade Inhibits Cardiac Inflammation and Fibrosis in Experimental Hyperaldosteronism and Hypertension. *Hypertension* **2015**, *66*, 767–775. [\[CrossRef\]](#)
14. Thijssen, V.L.; Heusschen, R.; Caers, J.; Griffioen, A.W. Galectin expression in cancer diagnosis and prognosis: A systematic review. *Biochim. Biophys. Acta* **2015**, *1855*, 235–247. [\[CrossRef\]](#)
15. De Boer, R.A.; Voors, A.A.; Muntendam, P.; Van Gilst, W.H.; Van Veldhuisen, D.J. Galectin-3: A novel mediator of heart failure development and progression. *Eur. J. Heart Fail.* **2009**, *11*, 811–817. [\[CrossRef\]](#)
16. Gehlken, C.; Suthahar, N.; Meijers, W.C.; de Boer, R.A. Galectin-3 in Heart Failure: An Update of the Last 3 Years. *Heart Fail. Clin.* **2018**, *14*, 75–92. [\[CrossRef\]](#)
17. Meijers, W.C.; Maglione, M.; Bakker, S.J.L.; Oberhuber, R.; Kieneker, L.M.; de Jong, S.; Haubner, B.J.; Nagengast, W.B.; Lyon, A.R.; van der Vegt, B.; et al. Heart failure stimulates tumor growth by circulating factors. *Circulation* **2018**, *138*, 678–691. [\[CrossRef\]](#)
18. De Boer, R.A.; van Veldhuisen, D.J.; Gansevoort, R.T.; Muller Kobold, A.C.; van Gilst, W.H.; Hillege, H.L.; Bakker, S.J.L.; van der Harst, P. The fibrosis marker galectin-3 and outcome in the general population. *J. Intern. Med.* **2012**, *272*, 55–64. [\[CrossRef\]](#)
19. Franchini, M.; Lippi, G. The intriguing relationship between the ABO blood group, cardiovascular disease, and cancer. *BMC Med.* **2015**, *13*, 7. [\[CrossRef\]](#)
20. Drechsler, C.; Delgado, G.; Wanner, C.; Blouin, K.; Pilz, S.; Tomaschitz, A.; Kleber, M.E.; Dressel, A.; Willmes, C.; Krane, V.; et al. Galectin-3, Renal Function, and Clinical Outcomes: Results from the LURIC and 4D Studies. *J. Am. Soc. Nephrol.* **2015**, *26*, 2213–2221. [\[CrossRef\]](#)
21. Gotsman, I.; Keren, A.; Zwas, D.R.; Lotan, C.; Admon, D. Clinical Impact of ABO and Rhesus D Blood Type Groups in Patients with Chronic Heart Failure. *Am. J. Cardiol.* **2018**, *122*, 413–419. [\[CrossRef\]](#)
22. Franchini, M.; Capra, F.; Targher, G.; Montagnana, M.; Lippi, G. Relationship between ABO blood group and von Willebrand factor levels: From biology to clinical implications. *Thromb. J.* **2017**, *5*, 14. [\[CrossRef\]](#) [\[PubMed\]](#)
23. Wolpin, B.M.; Chan, A.T.; Hartge, P.; Chanock, S.J.; Kraft, P.; Hunter, D.J.; Giovannucci, E.L.; Fuchs, C.S. ABO blood group and the risk of pancreatic cancer. *J. Natl. Cancer Inst.* **2009**, *101*, 424–431. [\[CrossRef\]](#) [\[PubMed\]](#)
24. Etemadi, A.; Kamangar, F.; Islami, F.; Poustchi, H.; Pourshams, A.; Brennan, P.; Boffetta, P.; Malekzadeh, R.; Dawsey, S.M.; Abnet, C.C.; et al. Mortality and cancer in relation to ABO blood group phenotypes in the Golestan Cohort Study. *BMC Med.* **2015**, *13*, 8. [\[CrossRef\]](#) [\[PubMed\]](#)
25. Franchini, M.; Mengoli, C.; Bonfanti, C.; Rossi, C.; Lippi, G. Genetic determinants of extreme longevity: The role of ABO blood group. *Thromb. Haemost.* **2015**, *115*, 458–460. [\[PubMed\]](#)
26. Chen, Z.; Yang, S.H.; Xu, H.; Li, J.J. ABO blood group system and the coronary artery disease: An updated systematic review and meta-analysis. *Sci. Rep.* **2016**, *6*, 23250. [\[CrossRef\]](#) [\[PubMed\]](#)
27. Parente, E.B.; Harjutsalo, V.; Lehto, M.; Forsblom, C.; Sandholm, N.; Groop, P.H. Relationship between ABO blood groups and cardiovascular disease in type 1 diabetes according to diabetic nephropathy status. *Cardiovasc. Diabetol.* **2020**, *19*, 68. [\[CrossRef\]](#)
28. Blais, C.; Germain, M.; Delage, G.; Grégoire, Y. The association between blood group and the risk of vascular disease in Quebec blood donors. *Blood Transfus.* **2016**, *14*, 455–459.
29. Biswas, S.; Ghoshal, P.K.; Halder, B.; Mandal, N. Distribution of ABO blood group and major cardiovascular risk factors with coronary heart disease. *Biomed Res. Int.* **2013**, *2013*, 782941. [\[CrossRef\]](#)
30. Yamamoto, F.; Clausen, H.; White, T.; Marken, J.; Hakomori, S. Molecular genetic basis of the histo-blood group ABO system. *Nature* **1990**, *345*, 229–233. [\[CrossRef\]](#)
31. Lowe, J.B. The blood group-specific human glycosyltransferases. *Baillieres. Clin. Haematol.* **1993**, *6*, 465–492. [\[CrossRef\]](#)

32. Franchini, M.; Liumbruno, G.M. ABO blood group: Old dogma, new perspectives. *Clin. Chem. Lab. Med.* **2013**, *51*, 1545–1553. [\[CrossRef\]](#)
33. Ewald, D.R.; Sumner, S.C.J. Blood type biochemistry and human disease. *Wiley Interdiscip. Rev. Syst. Biol. Med.* **2016**, *8*, 517–535. [\[CrossRef\]](#)
34. Reddy, V.M.; Daniel, M.; Bright, E.; Broad, S.R.; Moir, A.A. Is there an association between blood group O and epistaxis? *J. Laryngol. Otol.* **2008**, *122*, 366–368. [\[CrossRef\]](#)
35. Zhang, H.; Mooney, C.J.; Reilly, M.P. ABO blood groups and cardiovascular diseases. *Int. J. Vasc. Med.* **2012**, *2012*, 641917. [\[CrossRef\]](#)
36. Souto, J.C.; Almasy, L.; Muñoz-Díaz, E.; Soria, J.M.; Borrell, M.; Bayén, L.; Mateo, J.; Madoz, P.; Stone, W.; Blangero, J.; et al. Functional effects of the ABO locus polymorphism on plasma levels of von Willebrand factor, factor VIII, and activated partial thromboplastin time. *Arterioscler. Thromb. Vasc. Biol.* **2000**, *20*, 2024–2028. [\[CrossRef\]](#)
37. Matsui, T.; Titani, K.; Mizuochi, T. Structures of the asparagine-linked oligosaccharide chains of human von Willebrand factor. Occurrence of blood group A, B, and H(O) structures. *J. Biol. Chem.* **1992**, *267*, 8723–8731. [\[CrossRef\]](#)
38. Sarode, R.; Goldstein, J.; Sussman, I.I.; Nagel, R.L.; Tsai, H.M. Role of A and B blood group antigens in the expression of adhesive activity of von Willebrand factor. *Br. J. Haematol.* **2000**, *109*, 857–864. [\[CrossRef\]](#)
39. Nabi, I.R.; Shankar, J.; Dennis, J.W. The galectin lattice at a glance. *J. Cell Sci.* **2015**, *128*, 2213–2219. [\[CrossRef\]](#)
40. Chen, A.; Hou, W.; Zhang, Y.; Chen, Y.; He, B. Prognostic value of serum galectin-3 in patients with heart failure: A meta-analysis. *Int. J. Cardiol.* **2015**, *182*, 168–170. [\[CrossRef\]](#)
41. Meijers, W.C.; Januzzi, J.L.; Defilippi, C.; Adourian, A.S.; Shah, S.J.; van Veldhuisen, D.J.; de Boer, R.A. Elevated plasma galectin-3 is associated with near-term rehospitalization in heart failure: A pooled analysis of 3 clinical trials. *Am. Heart J.* **2014**, *167*, 853–860.e4. [\[CrossRef\]](#)
42. Meijers, W.C.; de Boer, R.A.; van Veldhuisen, D.J.; Jaarsma, T.; Hillege, H.L.; Maisel, A.S.; Di Somma, S.; Voors, A.A.; Peacock, W.F. Biomarkers and low risk in heart failure. Data from COACH and TRIUMPH. *Eur. J. Heart Fail.* **2015**, *17*, 1271–1282. [\[CrossRef\]](#)
43. Stowell, S.R.; Arthur, C.M.; Mehta, P.; Slanina, K.A.; Blixt, O.; Leffler, H.; Smith, D.F.; Cummings, R.D. Galectin-1, -2, and -3 exhibit differential recognition of sialylated glycans and blood group antigens. *J. Biol. Chem.* **2008**, *283*, 10109–10123. [\[CrossRef\]](#)
44. Feizi, T.; Solomon, J.C.; Yuen, C.T.; Jeng, K.C.; Frigeri, L.G.; Hsu, D.K.; Liu, F.T. The adhesive specificity of the soluble human lectin, IgE-binding protein, toward lipid-linked oligosaccharides. Presence of the blood group A, B, B-like, and H monosaccharides confers a binding activity to tetrasaccharide (lacto-N-tetraose and lacto-N-ne. *Biochemistry* **1994**, *33*, 6342–6349. [\[CrossRef\]](#)
45. Hirabayashi, J.; Hashidate, T.; Arata, Y.; Nishi, N.; Nakamura, T.; Hirashima, M.; Urashima, T.; Oka, T.; Futai, M.; Muller, W.E.; et al. Oligosaccharide specificity of galectins: A search by frontal affinity chromatography. *Biochim. Biophys. Acta.* **2002**, *1572*, 232–254. [\[CrossRef\]](#) [\[PubMed\]](#)
46. Wu, S.-C.; Ho, A.D.; Kamili, N.A.; Wang, J.; Murdock, K.L.; Cummings, R.D.; Arthur, C.M.; Stowell, S.R. Full-length galectin-3 is required for high affinity microbial interactions and antimicrobial activity. *Front. Microbiol.* **2021**, *12*, 731026. [\[CrossRef\]](#) [\[PubMed\]](#)
47. Stowell, S.R.; Arthur, C.M.; Dias-Baruffi, M.; Rodrigues, L.C.; Gouridine, J.-P.; Heimburg-Molinaro, J.; Ju, T.; Molinaro, R.J.; Rivera-Marrero, C.; Xia, B.; et al. Innate immune lectins kill bacteria expressing blood group antigen. *Nat. Med.* **2010**, *16*, 295–301. [\[CrossRef\]](#)
48. Paterson, A.D.; Lopes-Virella, M.F.; Waggott, D.; Boright, A.P.; Hosseini, S.M.; Carter, R.E.; Shen, E.; Mirea, L.; Bharaj, B.; Sun, L.; et al. Genome-Wide Association Identifies the ABO Blood Group as a Major Locus Associated with Serum Levels of Soluble E-Selectin. *Arterioscler. Thromb. Vasc. Biol.* **2009**, *29*, 1958. [\[CrossRef\]](#) [\[PubMed\]](#)
49. Redondo-Bermejo, B.; Pascual-Figal, D.A.; Hurtado-Martínez, J.A.; Montserrat-Coll, J.; Peñafiel-Verdú, P.; Pastor-Pérez, F.; Giner-Caro, J.A.; Valdés-Chávar, M. Clinical determinants and prognostic value of hemoglobin in hospitalized patients with systolic heart failure. *Rev. Española Cardiol.* **2007**, *60*, 597–606. [\[CrossRef\]](#)
50. Meijers, W.C.; van der Velde, A.R.; Ruifrok, W.P.; Schrotten, N.F.; Dokter, M.M.; Damman, K.; Assa, S.; Franssen, C.F.; Gansevoort, R.T.; van Gilst, W.H.; et al. Renal handling of galectin-3 in the general population, chronic heart failure, and hemodialysis. *J. Am. Heart Assoc.* **2014**, *3*, e000962. [\[CrossRef\]](#)
51. Mueller, C.; Laule-Kilian, K.; Scholer, A.; Nusbaumer, C.; Zeller, T.; Staub, D.; Perruchoud, A.P. B-type natriuretic peptide for acute dyspnea in patients with kidney disease: Insights from a randomized comparison. *Kidney Int.* **2005**, *67*, 278–284. [\[CrossRef\]](#)
52. Das, S.R.; Drazner, M.H.; Dries, D.L.; Vega, G.L.; Stanek, H.G.; Abdullah, S.M.; Canham, R.M.; Chung, A.K.; Leonard, D.; Wians, F.H.; et al. Impact of body mass and body composition on circulating levels of natriuretic peptides: Results from the Dallas Heart Study. *Circulation* **2005**, *112*, 2163–2168. [\[CrossRef\]](#)
53. Winkelmann, B.R.; März, W.; Boehm, B.O.; Zotz, R.; Hager, J.; Hellstern, P.; Senges, J. Rationale and design of the LURIC study—a resource for functional genomics, pharmacogenomics and long-term prognosis of cardiovascular disease. *Pharmacogenomics* **2001**, *2*, S1–S73. [\[CrossRef\]](#)
54. De Boer, R.A.; Schrotten, N.F.; Bakker, S.J.L.; Mahmud, H.; Szymanski, M.K.; van der Harst, P.; Gansevoort, R.T.; van Veldhuisen, D.J.; van Gilst, W.H.; Hillege, H.L. Plasma renin and outcome in the community: Data from PREVEND. *Eur. Heart J.* **2012**, *33*, 2351–2359. [\[CrossRef\]](#)

55. Diercks, G.F.; Janssen, W.M.; van Boven, A.J.; Bak, A.A.; de Jong, P.E.; Crijns, H.J.; van Gilst, W. Rationale, design, and baseline characteristics of a trial of prevention of cardiovascular and renal disease with fosinopril and pravastatin in nonhypertensive, nonhypercholesterolemic subjects with microalbuminuria (the Prevention of RENal and Vascular E. *Am. J. Cardiol.* **2000**, *86*, 635–638. [[CrossRef](#)]
56. Diercks, G.F.H.; van Boven, A.; Hillege, H.; Janssen, W.; Kors, J.; De Jong, P.; Grobbee, D.; Crijns, H.; van Gilst, W. Microalbuminuria is independently associated with ischaemic electrocardiographic abnormalities in a large non-diabetic population. The PREVEND (Prevention of RENal and Vascular ENdstage Disease) study. *Eur. Heart J.* **2000**, *21*, 1922–1927. [[CrossRef](#)]
57. Meijers, W.C.; Van Der Velde, A.R.; De Boer, R.A. The ARCHITECT galectin-3 assay: Comparison with other automated and manual assays for the measurement of circulating galectin-3 levels in heart failure. *Expert Rev. Mol. Diagn.* **2014**, *14*, 257–266. [[CrossRef](#)]
58. Christenson, R.H.; Duh, S.-H.; Wu, A.H.; Smith, A.; Abel, G.; Defilippi, C.R.; Wang, S.; Adourian, A.; Adiletto, C.; Gardiner, P. Multi-center determination of galectin-3 assay performance characteristics: Anatomy of a novel assay for use in heart failure. *Clin. Biochem.* **2010**, *43*, 683–690. [[CrossRef](#)]
59. Bedu-Addo, G.; Gai, P.P.; Meese, S.; Eggelte, T.A.; Thangaraj, K.; Mockenhaupt, F.P. Reduced prevalence of placental malaria in primiparae with blood group O. *Malar. J.* **2014**, *13*, 289. [[CrossRef](#)]
60. Pilz, S.; Tomaschitz, A.; Drechsler, C.; Ritz, E.; Boehm, B.O.; Grammer, T.B.; März, W. Parathyroid hormone level is associated with mortality and cardiovascular events in patients undergoing coronary angiography. *Eur. Heart J.* **2010**, *31*, 1591–1598. [[CrossRef](#)]

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.